RXST RXSIGHT INC

RxSight, Inc. to Present at the Bank of America Healthcare Conference

RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

RxSight’s management is scheduled to present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: .

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at .

Company Contact:

Shelley B. Thunen

Chief Financial Officer

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations



EN
01/05/2024

Underlying

RXSTRXSIGHT INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RXSIGHT INC

 PRESS RELEASE
Free
RXST RXSIGHT INC

RxSight, Inc. Announces Closing of its Public Offering of Common Stock...

RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase u...

May 13, 2024 1 EN
 PRESS RELEASE
Free
RXST RXSIGHT INC

RxSight, Inc. Announces Pricing of Public Offering of Common Stock

RxSight, Inc. Announces Pricing of Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public...

May 9, 2024 1 EN
 PRESS RELEASE
Free
RXST RXSIGHT INC

RxSight, Inc. Announces Proposed Public Offering of Common Stock

RxSight, Inc. Announces Proposed Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered...

May 8, 2024 1 EN
 PRESS RELEASE
Free
RXST RXSIGHT INC

RxSight, Inc. Reports First Quarter 2024 Financial Results

RxSight, Inc. Reports First Quarter 2024 Financial Results ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% ...

May 6, 2024 1 EN
 PRESS RELEASE
Free
RXST RXSIGHT INC

RxSight, Inc. to Present at the Bank of America Healthcare Conference

RxSight, Inc. to Present at the Bank of America Healthcare Conference ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference. RxSight’s management is scheduled to present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: . About RxSight, Inc. ...

May 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch